Explore KEYTRUDA® patient profile
Explore efficacy and safety profile results for KEYTRUDA® as monotherapy in locally advanced or metastatic UC for patients who progressed on or after platinum-containing chemotherapy
Discover results from the KEYNOTE-045 trialECOG=Eastern Cooperative Oncology Group; UC=urothelial carcinoma.
† Fictional patient. May not be representative of all patients.
Reference: 1. Merck Canada Inc. KEYTRUDA® Product Monograph. December 29, 2022. 2. Warren Canadian Urological Association (CUA)/Genitourinary Medical Oncologists of Canada (GMOC) consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. April 2019
CA-PDO-00146